Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia

Seom Gim Kong, Seri Jeong, Sangjin Lee, Jee-Yeong Jeong, Da Jung Kim and Ho Sup Lee

Abstract

Background: Transplantation-related mortality (TRM) is a major obstacle in allogeneic hematopoietic cell transplantation (allo-HCT). Approximately 60–80% of TRM occurs early, within 100 days of transplantation.

Methods: This was a nationwide population cohort study involving 5395 patients with acute leukemia who underwent allo-HCT between 2003 and 2015. Patient data were collected from the Korean National Health Insurance Service database. We investigated the cumulative incidence rates (CIRs) of early TRM at 50 and 100 days.

Results: The CIRs of early TRM at 50 and 100 days were 2.9 and 8.3%, respectively. There was no decrease in the CIRs of early TRM over time. The early mortality was significantly higher in patients with more than 9 months between the diagnosis and transplantation (CIRs of TRM at 50, 100 days; 6.0, 13.2%), previous transplantations (CIRs of TRM at 50, 100 days; 9.4, 17.2%), and cord blood transplantation (CIRs of TRM at 50, 100 days; 6.1, 8.3%). The early TRM was significantly lower in patients who received iron chelation before transplantation (CIRs of TRM at 50, 100 days; 0.3, 1.8%).

Conclusions: In conclusion, the overall CIR of early TRM was less than 10%. The predictable factors for early TRM included age, time from diagnosis to transplantation, the number of prior transplantations, the graft source, and previous iron chelation therapy.

Keywords: Cumulative incidence rates, Transplantation-related mortality, Risk factor, Hematopoietic stem cell transplantation, Acute leukemia

Introduction

Allogeneic hematopoietic cell transplantation (allo-HCT) is one of the most important treatment strategies for high-risk patients with acute leukemia. Although the complications and mortality associated with transplantation have decreased in recent years, transplantation-related mortality (TRM) is still the major barrier to allo-HCT [1–3]. Many studies have found that 60–80% of TRM occurs within 100 days of transplantation [3–6]. Recent large-scale studies in North America and Europe reported that the TRM at 100 days significantly decreased after the year 2000 [1, 2]. In this context, according to the Center for International Blood and Marrow Transplant Research (CIBMTR) study data, the 100-day TRM of acute myeloid leukemia patients with in first complete remission transplanted with using myeloablative conditioning (MAC) regimens decreased from 15 to 6% in matched sibling donors, and from 37 to 14% in matched unrelated donors [1]. In the European Society for Blood and Marrow...
Transplantation (EBMT) study, the TRM at 100 days decreased from 21.1 to 13.6% [2].

Some common causes of early TRM included infection, toxicity, and graft-versus-host disease (GVHD). Even within the first 100 days after allo-HCT, the cause of death varies as a result of the timing. The authors of the EBMT study reported that early mortality should be divided into the first 30 days (very early), and 30–100 days (early) after transplantation [2]. Infections and other causes accounted for more than 80% of the deaths occurring within 30 days of transplantation. Disease recurrence and GVHD accounted for 15% of the deaths. In contrast, relapses and GVHD accounted for more than 50% of the deaths between 30 and 100 days. Among non-relapse mortality, the mortality from GVHD decreased over time. However, mortality from other causes, such as infection and organ toxicity, was not significantly reduced. Similarly, an Italian study reported that mortality from acute GVHD has decreased significantly since 2001 although the mortality from infection and multi-organ failure increased [7].

Therefore, the objective of this study was to investigate changes in early TRM in Korea, using a large dataset from the National Health Insurance Service (NHIS) and analyzing the cumulative incidence rates (CIRs) of early TRM at 50 and 100 days after allo-HCT in patients with acute leukemia. We also investigated acute leukemia and the causes of early mortality and the associated risk factors associated with early TRM.

Methods

Data collection
This study was a nationwide, population-level, historical cohort study of patients with acute leukemia who underwent allo-HCT. This data was obtained from the claims database of the NHIS of the Republic of Korea. South Korea has a universal health coverage system provided by the central government, which has been unified since 2000. The NHIS provides health insurance to more than 99% of the population. Accordingly, the NHIS has a comprehensive health database for diagnoses, treatments, procedures, and prescriptions. They provide these extensive data for use in research after the approval process. This study also obtained death related data, including the cause of death from Statistics Korea, which has a comprehensive database in connection with the NHIS. In South Korea, death registration is usually completed and confirmed by a physician. The institutional review boards of Kosin University Gospel Hospital approved this study and granted a waiver of informed consent from the study participants owing to the nature of the data from which private information was deleted. All methods were carried out in accordance with relevant guidelines and regulations along with the approval.

Statistical methods
The objectives of this study were to determine the CIRs of early TRM at 50 and 100 days after transplantation and to identify the causes of death and risk factors for early TRM. The CIR of early TRM was reported at a specific time after the transplant (day 50 and 100) in a landmark approach. Patients who underwent two or more transplants in that period were analyzed for the last transplant. The probabilities of mortality were estimated using cumulative incidence curves. We used the chi-square test for categorical data and independent t-test for continuous data. The causes of death were reported within 50 days of allo-HCT. We used maximally selected log-rank statistics in the maxstat function of the R software (version 3.3.2) to identify the optimal threshold to assess the survival outcomes for age and time from diagnosis to transplantation. We selected the optimal age and time from diagnosis cut-offs to be 40 years and 9 months, respectively. The probability of overall survival was estimated by the Kaplan–Meier method. Logistic regression was used for multivariate analysis.

Study populations
We selected patients diagnosed with acute leukemia who received allo-HCT from 2003 to 2015. This study includes data on both adults and pediatric patients. Transplant data registered with the NHIS were from patients who reached complete remission prior to transplantation. The recipients and donors were typed at the allelic level for HLA-A, HLA-B, HLA-C, and HLA-DRB1 including those with fully matched or single-HLA locus mismatched transplants.

Treatment and procedures
The conditioning intensity was defined as MAC when the total body irradiation (TBI) was administered for 4 days or longer, or when busulfan was administered for 3 days or longer. In contrast, the cases in which TBI was administered for less than 4 days or busulfan for less than 3 days were classified as reduced-intensity conditioning (RIC). Rabbit anti-thymocyte globulin (ATG; Sanofi-Aventis, Cambridge, MA) was administered to patients at various dosages to prevent GVHD. ATG was given in equally divided doses for 2 or 3 days from day 3. All patients received calcineurin inhibitors, including cyclosporine or tacrolimus, with or without short-term methotrexate as immunosuppressants to prevent GVHD. Prophylaxis against infections included low-dose acyclovir, trimethoprim–sulfamethoxazole, antifungal agents (such as fluconazole), antibiotics (such as levofloxacin), and preemptive therapy with ganciclovir for patients with cytomegalovirus infection (on the basis of antigen or DNA testing). Half of the patients received ursodiol as prophylaxis against cholestasis.
The statistical analysis was performed using the R statistical software (version 3.4.4; R Foundation for Statistical Computing) and SAS statistical analysis software (version 9.4; SAS Institute Inc., Cary, NC, USA). *P*-values < 0.05 with 2 sided test were considered statistically significant.

**Results**

**Patient characteristics**
The characteristics of 5395 patients in the two transplant periods (from 2003 to 2009 and from 2010 to 2015) are shown in Table 1. The mean age of all patients was 35.9 ± 16.6 years (range, 0–72 years) at the time of transplantation, and 55.1% were male. The mean age at the time of transplantation has also increased from 31.8 to 38.3 years. Since 2010, the period from diagnosis to transplantation has been longer than that in the past. The number of patients who have had two or more transplants has also increased. However, the number of patients who required a high number of red blood cell (RBC) and platelet transfusions before transplantation decreased. Iron chelation was performed in some patients whose ferritin level was 1000 ng/mL or higher due to red blood cells transfusion. The number of patients who received iron chelating agents before transplantation increased from 5.2 to 20.1%.

The graft source of HCT in Korea has been changed. The use of peripheral blood increased from 55.8 to 85.8% and bone marrow decreased from 39.0 to 11.0%. The use of MAC decreased from 74.5 to 58.0%, while the use of RIC increased from 25.5 to 42.0%. TBI and busulfan-based conditioning regimens were used in approximately one-third and two-thirds of the patients, respectively. The number of patients who used ATG increased from 18.6 to 57.3%.

**The overall CIRs of early TRM and causes of mortality**
Accounting all, 151 and 442 patients died at 50 and 100 days after allo-HCT, respectively. The CIRs of early TRM were 2.9 and 8.3%, respectively (Fig. 1, Table 2). The CIRs of early mortality were significantly lower in elderly and high-risk patients has also increased [1, 2, 7, 8]. The independent high-risk factors of early TRM included older age (>40 years), longer duration from diagnosis to transplantation, previous transplantations, and cord blood transplantation. In particular, previous iron chelation therapy was an independent low-risk factor for early TRM (HR, 95% CI at 50 and 100 days; 0.07, 0.02–0.29, *p* < 0.001; 0.17, 0.10–0.29, *p* < 0.001).

**Risk factors for early TRM**
The detailed results of the CIRs of early TRM at 50 and 100 days (according to other variables) are shown Table 2 and Fig. 2. Since 2010, the early mortality did not change between the two periods. There was no significant difference in early TRM within 50 days according to age. However, the TRM at 100 days was higher in those 40 years old or older (< 40 vs ≥ 40; 7.1 vs. 9.4%, *p* = 0.003). Early mortality was significantly higher in patients with more than 9 months between diagnosis and transplantation (CIRs of TRM at 50, 100 days; 6.0, 13%, respectively). In addition, patients who underwent one or more previous transplantations showed significantly higher CIRs of early TRM at 50 and 100 days (9.4, 17.2%, respectively).

The CIRs of early TRM were significantly lower in patients who received previous iron chelation therapy at 50, 100 days (0.3, 1.8%, respectively) compared to that of those who did not receive iron chelation therapy. The average number of RBC transfusions was higher in the iron chelation group (6.4 ± 8.9 vs 3.7 ± 5.4, data was not shown) than it was in other groups. The CIRs of early TRM were higher for patients whose graft source was cord blood at 50 and 100 days (6.1, 18.3%, respectively) than they were in patients with other graft sources. The detailed results of univariate and multivariate analysis of early TRM at 50 and 100 days according to other variables are shown in Supplemental Table 2 and Table 3. The independent high-risk factors of early TRM included older age (≥40 years), longer duration from diagnosis to transplantation, previous transplantations, and cord blood transplantation. In particular, previous iron chelation therapy was an independent low-risk factor for early TRM (HR, 95% CI at 50 and 100 days; 0.07, 0.02–0.29, *p* < 0.001; 0.17, 0.10–0.29, *p* < 0.001).

**Discussion**
Total hematopoietic cell transplantation conducted in South Korea doubled over 10 years from 1139 cases in 2005 to 2286 cases in 2015 [8]. During our study period, the frequency of allo-HCT in acute leukemia also increased. In addition, the age of patients, the use of peripheral blood, RIC regimen, and the experience of iron chelation significantly increased. Globally, with advances in supportive care and RIC regimen, transplantation in elderly and high-risk patients has also increased [1, 2, 7, 8].
In North America and Europe, the average age of transplantation increased from 33 to 40 years since 2000 [1, 2]. According to the CIBMTR data from North America, the proportion of patients over 60 years old increased from 1% in 1994–1995 to 10% in 2004–2005 [1]. In addition, transplantations in patients with unrelated or mismatched donors, high risk disease status, and poor performance status increased [1, 7, 9, 11].

The CIRs of early TRM at 50 and 100 days for patients with acute leukemia between 2003 and 2015 were 2.9 and 8.3%, respectively. Other studies have reported the TRM at 100 days of 5–20%, and our results were similar [1, 2, 11]. In addition, many studies reported a significant decrease in the mortality of transplantation over time [1, 2, 7, 9, 10]. These studies explained these changes as a result of the use of less toxic conditioning, accurate HLA matching, advances in the prevention and treatment of GVHD, and improved engraftment with increased peripheral blood use [1, 7, 9, 10]. In our study, there was no significant decrease in early TRM over time. During this study period, the number of patients receiving iron chelation therapy increased, while the

| Table 1 Characteristics of patients who underwent allogeneic hematopoietic cell transplantation by time period (N = 5395) |
|---------------------------------------------------------------|
| Characteristics                                               | Total (%) | 2003–2009 (%) | 2010–2015 (%) | p-value |
| Number                                                       | 5395      | 1958          | 3437          |
| Recipient age, years                                         |           |               |               |
| Mean                                                         | 35.9 ± 16.6 | 31.8 ± 16.2 | 38.3 ± 16.3 | < 0.001 |
| 0–19                                                        | 1145 (21.2) | 532 (27.2)   | 613 (17.8)   | < 0.001 |
| 20–39                                                       | 1707 (31.7) | 700 (35.7)   | 1007 (29.3)  |
| 40–59                                                       | 2229 (41.3) | 679 (34.7)   | 1550 (45.1)  |
| ≥ 60                                                        | 314 (5.8)    | 47 (2.4)     | 267 (7.8)    |
| Recipient sex                                                |           |               |               |
| Male                                                        | 2973 (55.1) | 1074 (54.9)  | 1899 (55.3)  | 0.798   |
| Female                                                      | 2422 (44.9) | 884 (45.1)   | 1538 (44.7)  |
| Diagnosis                                                   |           |               |               |
| ALL                                                         | 1905 (35.3) | 673 (34.4)   | 1232 (35.8)  | 0.290   |
| AML                                                         | 3490 (64.7) | 1285 (65.6)  | 2205 (64.2)  |
| Time from diagnosis to transplantation, months               | 8.8 ± 12.1 | 7.7 ± 8.2    | 9.5 ± 13.7   | < 0.001 |
| Previous transplantation (≥1)                               | 331 (6.1)   | 87 (4.4)     | 244 (7.1)    | < 0.001 |
| RBC transfusion before HCT (≥3)                             | 2324 (43.1) | 889 (45.4)   | 1435 (41.8)  | 0.010   |
| PLT transfusion before HCT (≥4)                             | 2322 (43.0) | 882 (45.0)   | 1440 (41.9)  | 0.027   |
| Previous iron chelation therapy                             | 793 (14.7)  | 102 (5.2)    | 691 (20.1)   | < 0.001 |
| Graft source                                                |           |               |               |
| Peripheral blood                                            | 4041 (74.9) | 1093 (55.8)  | 2948 (85.8)  | < 0.001 |
| Bone marrow                                                 | 1141 (21.1) | 764 (39.0)   | 377 (11.0)   |
| Cord blood                                                  | 213 (3.9)   | 101 (5.2)    | 112 (3.3)    |
| Conditioning intensity                                      |           |               |               |
| MAC                                                         | 3453 (64.0) | 1459 (74.5)  | 1994 (58.0)  | < 0.001 |
| RIC                                                         | 1942 (36.0) | 499 (25.5)   | 1443 (42.0)  |
| Conditioning regimen                                        |           |               |               |
| TBI-based                                                   | 1754 (32.5) | 629 (32.1)   | 1125 (32.7)  | < 0.001 |
| Busulfan-based                                              | 3272 (60.6) | 1136 (58.0)  | 2136 (62.1)  |
| Non-TBI, Non-busulfan                                       | 369 (6.8)   | 193 (9.9)    | 176 (5.1)    |
| Use of ATG                                                  |           |               |               |
| No                                                         | 3061 (56.7) | 1593 (81.4)  | 1468 (42.7)  | < 0.001 |
| Yes                                                        | 2334 (43.3) | 365 (18.6)   | 1969 (57.3)  |

ALL Acute lymphocytic leukemia; AML Acute myeloid leukemia; RBC Red blood cell; HCT Hematopoietic cell transplantation; PLT Platelet; MAC Myeloablative conditioning; RIC Reduced-intensity conditioning; TBI Total body irradiation; ATG Antithymocyte globulin
Values are presented as means ± standard deviations or numbers of cases (%)
number of elderly patients and patients who had previous transplantation also increased. On the other hand, the use of bone marrow decreased. In addition, although we have not investigated, unrelated transplantation would have increased as in other studies \[1, 9\]. For this reason, we speculated that there was no significant improvement in early TRM in our study.

This study showed that the most common causes of death within 50 days of transplant were infection (pneumonia, sepsis) and organ failure. In previous studies, the most common causes of early TRM were infection (pneumonia), organ failure, GVHD, and relapse \[2, 7\]. However, similar to our findings, other groups have found that infection or organ failure were related to death at very early periods after transplantation \[2, 12\].

In this study, there were significantly higher CIRs of early TRM in the following settings: older age, a long time from diagnosis to transplantation, previous transplantations, the use of cord blood as a graft source, and the absence of iron chelation therapy before transplantation. Many studies have evaluated the risk factors related to TRM, including age, disease status, donor matching, stem cell source, and interval between transplants \[3, 5–7, 9, 11–15\]. Old age was an important risk

---

**Fig. 1** Cumulative incidence rates (CIRs) of early transplant-related mortality after HCT. (A) CIRs of early mortality at 50 and 100 days after transplantation in patients with acute leukemia were 2.9 and 8.3%, respectively. (B) In children and adults, the CIRs of early mortality at 50 days were 1.9 and 3.2% \((p = 0.044)\), and the CIRs of early mortality at 100 days were 6.6 and 8.7% \((p = 0.024)\), respectively.
In our study, age over 40 years old was a factor affecting early mortality. However, TRM was not higher in patients over 60 years old than it was in those under 60.

In addition, cord blood transplantation was associated with higher early TRM. Patients receiving cord blood usually had longer neutrophil recovery time than did those receiving bone marrow or peripheral blood [16]. The delayed engraftment can result in high early mortality caused by neutropenic fever or sepsis. Patients who underwent previous transplantations presented with relapse or refractory disease status after the first transplantation. Patients who underwent second transplantation showed non-relapse mortality greater than 30% [17, 18]. Patients with a high risk of relapse or refractory disease who underwent previous transplantations had a high incidence of TRM [12].

Another significant factor for TRM was iron chelation treatment. Iron overload was already known as a major adverse prognostic factor in transplantation of benign hematologic diseases such as thalassemia [19]. In addition, it has been reported to be associated with low

Table 2: The cumulative incidence rates of early transplant-related mortality after allogeneic hematopoietic cell transplantation

| Variables                                      | Total   | Number of early TRM (%) | Within 50 days | p-value | Within 100 days | p-value |
|------------------------------------------------|---------|--------------------------|----------------|---------|----------------|---------|
|                                                  |         |                         |                |         |                |         |
| Total                                           | 5395    | 151 (2.9)                |                |         | 442 (8.3)      |         |
| Year of transplantation                         |         |                         |                |         |                |         |
| 2003–2009                                       | 1958    | 47 (2.4)                 | 0.210          | 160 (8.2) | 1.000          |         |
| 2010–2015                                       | 3437    | 104 (3.0)                |                |         | 282 (8.2)      |         |
| Recipient age, years                            |         |                         |                |         |                |         |
| Mean                                            | 35.9 ± 16.6 | 39.1 ± 16.3         | 0.017          | 380 ± 16.9 | 0.005          |         |
| 0–19                                            | 1145    | 22 (1.9)                 | 0.164          | 76 (6.6)  | 0.015          |         |
| 20–39                                           | 1707    | 47 (2.8)                 |                | 127 (7.4) |               |         |
| 40–59                                           | 2229    | 73 (3.3)                 |                | 213 (9.6) |               |         |
| ≥ 60                                            | 314     | 9 (2.9)                  |                | 26 (8.3)  |               |         |
| Recipient sex                                    |         |                         |                |         |                |         |
| Male                                            | 2973    | 69 (2.3)                 | 0.023          | 239 (8.0) | 0.685          |         |
| Female                                          | 2422    | 82 (3.4)                 |                | 203 (8.4) |               |         |
| Diagnosis                                       |         |                         |                |         |                |         |
| ALL                                             | 1905    | 65 (3.4)                 | 0.054          | 179 (9.4) | 0.020          |         |
| AML                                             | 3490    | 86 (2.5)                 |                | 263 (7.5) |               |         |
| Time from diagnosis to transplantation, months   |         |                         |                |         |                |         |
| < 9                                             | 4434    | 93 (2.1)                 | < 0.001        | 315 (7.1) | < 0.001        |         |
| ≥ 9                                             | 961     | 58 (6.0)                 |                | 127 (13.2) |               |         |
| Previous transplantations                       |         |                         |                |         |                |         |
| No                                              | 5064    | 120 (2.4)                | < 0.001        | 385 (7.6) | < 0.001        |         |
| Yes                                             | 331     | 31 (9.4)                 |                | 57 (17.2) |               |         |
| Previous iron chelation therapy                 |         |                         |                |         |                |         |
| No                                              | 4602    | 149 (3.2)                | < 0.001        | 428 (9.3) | < 0.001        |         |
| Yes                                             | 793     | 2 (0.3)                  |                | 14 (1.8)  |               |         |
| Graft source                                    |         |                         |                |         |                |         |
| Peripheral blood                                | 4041    | 119 (2.9)                | < 0.001        | 333 (8.2) | < 0.001        |         |
| Bone marrow                                     | 1141    | 19 (1.7)                 |                | 70 (6.1)  |               |         |
| Cord blood                                      | 213     | 13 (6.1)                 |                | 39 (18.3) |               |         |
| Use of ATG                                      |         |                         |                |         |                |         |
| No                                              | 3061    | 77 (2.5)                 | 0.173          | 229 (7.5) | 0.033          |         |
| Yes                                             | 2334    | 74 (3.2)                 |                | 213 (9.1) |               |         |

TRM Transplant-related mortality; ALL Acute lymphocytic leukemia; AML Acute myeloid leukemia; ATG Antithymocyte globulin

Values are presented as means ± standard deviations or numbers of cases (%)

factor for early TRM [1, 2, 6, 11]. In our study, age over 40 years old was a factor affecting early mortality. However, TRM was not higher in patients over 60 years old than it was in those under 60.

In addition, cord blood transplantation was associated with higher early TRM. Patients receiving cord blood usually had longer neutrophil recovery time than did those receiving bone marrow or peripheral blood [16]. The delayed engraftment can result in high early mortality caused by neutropenic fever or sepsis. Patients who underwent previous transplantations presented with relapse or refractory disease status after the first transplantation. Patients who underwent second transplantation showed non-relapse mortality greater than 30% [17, 18]. Patients with a high risk of relapse or refractory disease who underwent previous transplantations had a high incidence of TRM [12].

Another significant factor for TRM was iron chelation treatment. Iron overload was already known as a major adverse prognostic factor in transplantation of benign hematologic diseases such as thalassemia [19]. In addition, it has been reported to be associated with low
survival and high TRM in allo-HCT of hematologic malignancies [20–25]. Pullarkat et al. found that early mortality at 100 days and the risk of death (due to acute GVHD and infection) increased when pre-transplantation ferritin levels were higher than 1000 ng/mL [23]. Deaths from iron overload were caused by organ toxicity and liver toxicity, such as venous occlusive disease [24, 26]. Iron chelation has been found to reduce mortality in patients who were at risk of high mortality due to iron overload [27, 28]. Sivgin et al. reported that peri-transplant mortality at 100 days after allo-HCT was 18.9% in patients who did not receive iron chelation and 2.3% in patients who received iron chelation therapy [27].

In our study, a total of 14.7% of patients received iron chelating agents before transplantation. The CIR of early TRM was significantly lower in patients who received iron chelating agents than it was in those who did not receive this therapy. We did not analyze the pre-transplant ferritin levels or the duration of iron chelation in this study. Although the average number of RBC transfusions was significantly higher in patients who underwent iron chelation than it was in those who did not, the mortality rate was low. Some authors have reported that severe iron overload itself was detrimental, but also that toxic non-transferrin-bound iron caused by conditioning was associated with tissue damage [20, 29]. Under this background, Armand et al. administered deferoxamine for 2 weeks before transplantation to 5 patients with median ferritin level of 3746 ng/mL [30]. Veno-occlusive disease did not occur in all of them and all survived until 22 months. In general, the iron overload rate of patients before receiving allo-HCT was as high as 30–70% [25, 31]. Although the use of iron

Fig. 2 The comparison of cumulative incidence rates of early transplant-related mortality according to the variables. (A) age, (B) time from diagnosis to transplantation, (C) previous number of transplantations, (D) previous therapy with iron chelation, and (E) graft sources.
chelation has increased, more active treatment for iron overload is needed.

This study had several limitations. First, it was limited to patients who were registered with the NHIS in Korea. In addition, because of the limitation of big data, we were not able to analyze disease status, donor type, recurrence, or detailed clinical findings. However, this study was a meaningful retrospective study that was based on large-scale transplant data conducted in Korea over 14 years. In conclusion, the CIRs of early TRM at 50 and 100 days were similar to those reported in previous studies (2.9 and 8.3%). The most common causes of death were infection and organ failure. The highest rates of early TRM were found in patients who were older, had a long period to transplantation, underwent previous transplantations, and received cord blood as the graft source. Patients who received iron chelation therapy before transplantation had a low incidence rate of early TRM.

### Table 3 Multivariate analysis for early transplant-related mortality

| Variables                              | Within 50 days | Within 100 days |
|----------------------------------------|----------------|-----------------|
|                                        | HR 95% CI      | p-value         | HR 95% CI      | p-value         |
| Older age (≥40)                        | 1.68 (1.20–2.36) | 0.003           | 1.63 (1.34–1.98) | < 0.001         |
| Diagnosis                              |                |                 |                |                 |
| ALL                                    | Reference      | Reference       |                |                 |
| AML                                    | 0.75 (0.54–1.05) | 0.097           | 0.82 (0.68–1.00) | 0.050           |
| Longer D-to-HCT duration (≥9 months)   | 2.09 (1.39–3.13) | < 0.001         | 1.58 (1.23–2.03) | < 0.001         |
| Previous transplantation               | 2.51 (1.55–4.08) | < 0.001         | 1.79 (1.28–2.49) | 0.001           |
| Previous iron chelation therapy        | 0.07 (0.02–0.29) | < 0.001         | 0.17 (0.10–0.29) | < 0.001         |
| Graft source                           |                |                 |                |                 |
| Peripheral blood                       | Reference      | Reference       |                |                 |
| Bone marrow                            | 0.61 (0.37–1.01) | 0.054           | 0.80 (0.61–1.04) | 0.097           |
| Cord blood                             | 2.01 (1.11–3.64) | 0.022           | 2.44 (1.73–3.45) | < 0.001         |
| Use of ATG                             | 1.07 (0.77–1.50) | 0.690           | 1.17 (0.96–1.42) | 0.125           |

HR Hazard ratio; 95% CI 95% Confidence interval; ALL Acute lymphocytic leukemia; AML Acute myeloid leukemia; D-to-HCT Diagnosis to hematopoietic cell transplantation; ATG Antithymocyte globulin

Acknowledgements
The authors acknowledge the efforts of the staff of the HIRA database, which is supported by the NHI system of Korea. This study was supported in part by the Korean National Research Foundation (KNRF) grant 2017R1C1B2004597 (to Seri Jeong), KNRF grant 2019R1G1A1010388 (to Da Jung Kim), and KNRF grants 2019M3A9H11103607 and 2017M3A9G7072564 (both to Ho Sup lee and Jee-Yeong Jeong).

Authors’ contributions
Seom Gim Kong, and Ho Sup Lee designed the study and were the main writers of the manuscript. Sangjin Lee analyzed the data. Seri Jeong, Jee-Yeong Jeong and Da Jung Kim reviewed the data. All authors read and approved the final manuscript.

Availability of data and materials
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Raw data generated at National Health Insurance Service are not available because of the personally identifiable information. If one researcher wants to access data, the researcher should submit the security memorandum and pledge to the Institutional Review Board of National Health Insurance Sharing Service. After approval, the researcher can receive data with blind identification and the data must be analyzed only in permitted rooms in centers of National Health Insurance Service. Contact information for a data access committee is listed as follows: National Health Insurance Sharing Service, Tel: 82–33–736-2432; Official internet site: https://nhiss.nhis.or.kr/bd/ay/bdaya001iv.do

Ethics approval and consent to participate
This study was approved by the independent Institutional Review Board of Kosin University Gospel Hospital (KUGH 2017–11–026) and conducted in accordance with the Declaration of Helsinki. This study was exempted from the requirement for informed patient consent because personal information was protected and kept anonymous.
Consent for publication
Not applicable.

Competing interests
There are no potential competing interests relevant to this article to report.

Author details
1Department of Pediatrics, Kosin University College of Medicine, Busan, South Korea. 2Department of Laboratory Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea. 3Graduate School, Department of Statistics, Pusan National University, Busan, South Korea. 4Department of Biochemistry, Kosin University College of Medicine, Busan, South Korea. 5Institute for Medical Science, Kosin University College of Medicine, Busan, South Korea. 6Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan, South Korea.

Received: 11 November 2020 Accepted: 9 February 2021

Published online: 18 February 2021

References
1. Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.
2. Szychowski J, Tridello G, Koster L, Iacobelli S, van Biesen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55:126–36.
3. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, et al. Hematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2007;39:89–99.
4. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26:397–404.
5. Cornelissen JJ, Canston M, Kollman C, Ring R, Dekker AW, Livengen B, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572–7.
6. Bunin NJ, Davies SM, Aplenc R, Camitta BM, Desantes KB, Goyal RK, et al. Unrelated bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol. 2008;26:4226–32.
7. Bacigalupo A, Semer MPM, Lamparelli T, Gualandi F, Occhini D, Bregante S, et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004;89:1238–47.
8. Iida M, Kodenia Y, Dodds A, Ho AYL, Nivison-Smith I, Akter MR, et al. Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015. Bone Marrow Transplant. 2010;54:1073–86.
9. Remberger M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Dlugosz A, et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant. 2011;17:1688–97.
10. Gooley TA, Chien JW, Pergam SA, Hingorani S, Borrok ML, Boedek M, et al. Reduced mortality after allogeneic hematopoietic-erythroid-cell transplantation. N Engl J Med. 2010;363:1091–101.
11. Horan JT, Logan BR, Agovi-Johnson M-A, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplant-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29:8950–53.
12. Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99:2002–8.
13. Bunin N, Canston M, Wall D, Adams R, Casper J, Karnani N, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood. 2002;99:3151–7.
14. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4567–83.
15. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110:1379–87.
16. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizziere DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815–22.
17. Moukalmd NM, Kharfan-Dabaja MA. What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? Bone Marrow Transplant. 2020;55:325–31.
18. Ortiz G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Española de Trasplante Hematopoietico. Biol Blood Marrow Transplant. 2016;22:584–8.
19. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Barociani D, Giardini C, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417–21.
20. Altés A, Remacha AF, Sureda A, Martino R, Briñez J, Canals C, et al. Iron overload might increase transplant-related mortality in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:887–9.
21. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Aljea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloblastic stem cell transplantation. Blood. 2007;109:4586–8.
22. Kim YR, Kim JS, Cheung JW, Song JW, Min YH. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematol. 2008;119:208–12.
23. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42:799–805.
24. Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T, et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloblastic and nonmyeloblastic allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:195–204.
25. Wang Z, Jia M, Zhao H, Cheng Y, Luo C, Chen Y, et al. Prognostic impact of pretransplantation hyperferritinemia in adults undergoing allogeneic hematopoietic SCT: a meta-analysis. Bone Marrow Transplant. 2014;49:1339–40.
26. Maradei SC, Maiolino A, de Azevedo AM, Colares M, Bouzas LF, Nucci M. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood. 2009;114:1270–7.
27. Sivgin S, Baldane S, Akyol G, Keklik M, Kaynar L, Kurnaz F, et al. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHCT) recipients with transfusional iron overload. Transfus Apher Sci. 2013;49:295–301.
28. Leitch HA, Parram A, Wells RA, Chodirker L, Zhu N, Nevill TJ, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2011;154:793–9.
29. Sahilstedt L, Ebeling F, von Bonsdorff L, Parkkinnen J, Ruutu T. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol. 2001;113:836–8.
30. Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, et al. Pretransplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloblastic allo-SCT. Bone Marrow Transplant. 2013;48:1467–7.
31. Atilla E, Toprak SK, Demirer T. Current review of iron overload and related complications in hematopoietic stem cell transplantation. Turk J Haematol. 2017;34:1–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.